HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- butyryl- 4- (5R- methylbenzylamino)- 8- ethoxy- 1,7- naphthyridine

structure in first source

Also Known As:

YJA 20379-8; YJA-20379-8; YJA20379-8

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Naphthyridines: 2
      - 3-butyryl-4-(5R-methylbenzylamino)-8-ethoxy-1,7-naphthyridine: 4

Experts

1.	Chang, H O: 1 article (01/2001)
2.	Chang, M S: 1 article (01/2001)
3.	Cho, S I: 1 article (01/2001)
4.	Choi, W S: 1 article (01/2001)
5.	Kim, K B: 1 article (01/2001)
6.	Lee, E B: 1 article (01/2001)
7.	Lee, S B: 1 article (01/2001)

Related Diseases

1.	Acute Kidney Injury (Acute Renal Failure) 10/01/1998 - "Because the physiological changes that occur in patients with acute renal failure could alter the pharmacokinetics of the drugs used to treat the disease, the pharmacokinetics of YJA-20379-8, a new reversible proton pump inhibitor, were investigated after 15-min intravenous (20 mg/kg) and oral (50 mg/kg) administration to control rats and rats with uranyl nitrate-induced acute renal failure (U-ARF). " 10/01/1998 - "Pharmacokinetic changes of a new proton pump inhibitor, YJA-20379-8, after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure."
2.	Ulcer 01/01/2001 - "The general pharmacological properties of YJA20379-8 (3-butyryl-4-[(R)-1-methylbenzylamino]-8-ethoxy-1,7-naphthyridine, CAS 187654-40-6), a new H+/K(+)-ATPase inhibitor with anti-ulcer activities, were investigated in mice, rats and guinea pigs. " 01/01/2001 - "General pharmacological properties of YJA20379-8, a new H+/K(+)-ATPase inhibitor with anti-ulcer activities."
3.	Stomach Ulcer (Gastric Ulcer) 09/01/1999 - "The results suggest that modification of the oral dose of YJA-20379-8 may not be required in gastric ulcer patients if the present rat pharmacokinetic data could be extrapolated to man." 09/01/1999 - "Gastrointestinal absorption of a new reversible proton pump inhibitor, YJA-20379-8, and its pharmacokinetics after oral administration in acetic acid-induced gastric ulcer in rats."
4.	Diabetes Mellitus 08/01/1999 - "Because physiological changes occurring in diabetes mellitus patients could alter the pharmacokinetics of the drugs used to treat the disease, the pharmacokinetics of a new proton pump inhibitor, YJA-20379-8, were investigated after intravenous and oral administration of the drug (50 mg kg(-1)) to control rats and to rats with streptozotocin-induced diabetes mellitus (SIDM). " 08/01/1999 - "Pharmacokinetics of a new proton-pump inhibitor, YJA-20379-8, after intravenous and oral administration to rats with streptozotocin-induced diabetes mellitus."

Related Drugs and Biologics

1.	Proton Pump Inhibitors
2.	Acetic Acid (Vinegar)
3.	Uranyl Nitrate
4.	Streptozocin (Streptozotocin)
5.	Adenosine Triphosphatases (ATPase)

Related Therapies and Procedures

1.	Oral Administration